

| CERTIFICATE OF MAILING  |                       |      |        |
|---|-----------------------|------|--------|
| I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231. |                       |      |        |
| Typed or Printed Name   | <i>Conley, Thomas</i> |      |        |
| Signature   | <i>Conley, Thomas</i> | Date | 1/1/02 |

|  |                                  |   |
|--|----------------------------------|---|
| <b>AMENDMENT UNDER<br/>37 C.F.R. §1.111</b><br><br>Address to:<br>Assistant Commissioner for Patents<br>Washington, D.C. 20231 | Attorney Docket Confirmation No. | UCAL263CIP<br>4882  |
|  | First Named Inventor             | J.S. Reid   |
|  | Application Number               | 09/739,933  |
|  | Filing Date                      | December 18, 2000   |
|  | Group Art Unit                   | 1647  |
|  | Examiner Name                    | S.L. Turner   |
|  | Title                            | Compositions and methods for manipulating glial progenitor cells and treating neurological deficits |

18/a  
M.G.J.  
2/4/03

Sir:

This amendment is responsive to the Office Action dated August 5, 2002 for which a three-month period for response was given making this response due on or before November 5, 2002. *A Petition for a one-Month Extension of Time is submitted herewith, making this amendment due on or before December 5, 2002.* Accordingly, this response is timely filed.

In view of the remarks put forth below, reconsideration and allowance are respectfully requested.

# **I. AMENDMENTS**

## **IN THE CLAIMS**

Cancel claim 27 without prejudice to renewal.

Please enter the amendments to claims 1, 20, and 33, as shown below.

Please enter new claims 63 and 64, as shown below.

a' 1. (Amended) A method for attracting a glial progenitor cell, or a progeny of a glial progenitor cell, to a site of damage or lesion in a central nervous system (CNS) tissue, the method comprising administering a sufficient amount of a compound that binds to an epidermal growth factor (EGF)/ ErbB family receptor, wherein said administration is outside of the ventricles, and wherein the glial progenitor cell or progeny thereof is attracted to the site of damage or lesion in the central nervous system (CNS) tissue.

*administrative not to site*

02/04/2003 STRANHEL 00000001 300813 09739933

01 FC:2201 42.00 CH  
02 FC:2202 9.00 CH